Prostate cancer is the most common cancer in men and the second leading cause of cancer related mortality. The incidence in Afro-American males is 37% higher than in Caucasians. Although the risk factors for prostate cancer remain unclear, diet and serum testosterone levels may play a role.

Screening for prostate cancer has been advocated. A digital rectal examination, measurement of Prostate specific antigen (PSA) and transrectal ultrasound (TRUS) may detect the tumor at an early time. Currently a large prostate prevention trial is underway.

Treatment of prostate cancer varies according to the extent of disease and the overall health of the patient. Surgery, radiation, hormonal manipulation and chemotherapy may all have roles in selected individuals.

For many elderly patients in whom the prostate cancer has not spread, supportive care alone may be appropriate. In younger patients with well localized disease (confined to the prostate itself) surgery and/or radiation may be initial treatments. For patients with prostate cancer that involves lymph nodes or prostate cancer that has spread (such as to the bones) treatments may involve radiation and/or hormones (anti-testosterone treatments). Chemotherapy is typically reserved for patients with advanced disease.

Prostate cancers are not currently treated with transplantation at Hackensack University Medical Center. However, the physicians at the Northern New Jersey Cancer Center are experienced in the diagnosis and treatment of this disease. Active research studies on pancreatic cancer include:

1. A phase III trial of three different doses of Suramin in advanced disease
2. Intermittent androgen deprivation in patients with Stage D2 prostate cancer

For more information on these protocols call (201) 996-5900.